Treatment of Multidrug-resistant Pseudomonas aeruginosa Bacteremia in a Immunocompromised Child With Ceftolozane-tazobactam
Pediatric Infection & Vaccine
; : 47-54, 2023.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-1002702
Responsible library:
WPRO
ABSTRACT
With the widespread use of broad-spectrum antibiotics in clinical practice, the emergence of multidrug-resistant (MDR) gram-negative bacteria has become a global problem. The MDR Pseudomonas aeruginosa infection is especially difficult to treat and increases mortality in critically ill patients. Ceftolozane-tazobactam (Zerbaxa™) is a fifth-generation cephalosporin and beta-lactamase inhibitor that has proved to be effective for treating complicated urinary tract infections and complicated intra-abdominal infections caused by MDR P. aeruginosa. Herein, we report the first case of pediatric hematologic cancer in Korea that was successfully treated for MDR P. aeruginosa bacteremia with Ceftolozane-tazobactam.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
English
Journal:
Pediatric Infection & Vaccine
Year:
2023
Document type:
Article